ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone978-646-1400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$769.43 million
Profitability
Miscellaneous
Employees1,371
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
ABIOMED (NASDAQ:ABMD) Frequently Asked Questions
What is ABIOMED's stock symbol?
ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."
How were ABIOMED's earnings last quarter?
ABIOMED, Inc. (NASDAQ:ABMD) issued its quarterly earnings data on Thursday, August, 1st. The medical equipment provider reported $1.00 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.99 by $0.01. The medical equipment provider earned $207.70 million during the quarter, compared to analysts' expectations of $210.96 million. ABIOMED had a net margin of 32.35% and a return on equity of 19.84%. ABIOMED's revenue for the quarter was up 15.4% on a year-over-year basis. During the same period in the previous year, the company earned $1.95 earnings per share. View ABIOMED's Earnings History.
When is ABIOMED's next earnings date?
What guidance has ABIOMED issued on next quarter's earnings?
ABIOMED issued an update on its FY 2020 earnings guidance on Thursday, August, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $885-925 million, compared to the consensus revenue estimate of $927.1 million.
What price target have analysts set for ABMD?
5 analysts have issued 12-month price targets for ABIOMED's shares. Their predictions range from $215.00 to $400.00. On average, they expect ABIOMED's stock price to reach $318.3333 in the next year. This suggests a possible upside of 64.9% from the stock's current price. View Analyst Price Targets for ABIOMED.
What is the consensus analysts' recommendation for ABIOMED?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ABIOMED in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ABIOMED.
What are Wall Street analysts saying about ABIOMED stock?
Here are some recent quotes from research analysts about ABIOMED stock:
- 1. According to Zacks Investment Research, "ABIOMED wrapped up fourth-quarter fiscal 2019 on a mixed note. Competition in the MedTech industry is intense. Pricing pressure and foreign currency headwinds persist. ABIOMED has underperformed the industry in a year’s time. However, the company continues to gain from its flagship Impella, which saw a strong quarter. Impella’s patient success stories and increasing global adoption are added positives. Revenues from Japan also skyrocketed in the quarter. Considerable expansion in the operating margin buoys optimism. Meanwhile, surging R&D expenses show increasing focus on innovation. In fact, the company continues to invest in training and education. The recent CE Mark of the Impella Connect is encouraging as well. The company’s balance sheet is debt-free." (5/8/2019)
- 2. BTIG Research analysts commented, "Term; Trimming PT to $340 From $400 Abiomed missed estimates in the quarter, delivering sales of $207M, short of consensus’ $219M forecast. Most of the weakness was U.S. driven, due to a weak cath lab (also seen in peer results) and to a greater extent, mix disruption leading to mgmt’s disproportionate focus away from protected PCI/elective procedures. To reflect these pressures, mgmt’s initial FY20 outlook calls for revenue growth of 17-23%, 6% below what mgmt (and we) would’ve considered more likely (and exactly the exact magnitude of the FQ4 shortfall). Mgmt outlined a number of initiatives to address these issues and noted that April is reportedly promising. The fact that mgmt still remains confident in addressable market and has left room to revise guidance during its next earnings call suggest there is good chance of upside." (5/7/2019)
Has ABIOMED been receiving favorable news coverage?
News headlines about ABMD stock have trended negative on Saturday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ABIOMED earned a news impact score of -2.3 on InfoTrie's scale. They also gave news articles about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for ABIOMED.
Are investors shorting ABIOMED?
ABIOMED saw a decrease in short interest during the month of July. As of July 31st, there was short interest totalling 2,134,600 shares, a decrease of 6.7% from the June 30th total of 2,287,500 shares. Based on an average daily volume of 645,300 shares, the days-to-cover ratio is presently 3.3 days. Currently, 4.9% of the shares of the stock are sold short. View ABIOMED's Current Options Chain.
Who are some of ABIOMED's key competitors?
Some companies that are related to ABIOMED include FRESENIUS SE &/S (FSNUY), ResMed (RMD), Teleflex (TFX), DexCom (DXCM), Insulet (PODD), Novocure (NVCR), Hill-Rom (HRC), Haemonetics (HAE), Integra Lifesciences (IART), Penumbra (PEN), Globus Medical (GMED), Cantel Medical (CMD), Tandem Diabetes Care (TNDM), ICU Medical (ICUI) and NuVasive (NUVA).
What other stocks do shareholders of ABIOMED own?
Who are ABIOMED's key executives?
ABIOMED's management team includes the folowing people:
- Mr. Michael R. Minogue, Chairman, CEO & Pres (Age 52)
- Dr. David M. Weber, Chief Operating Officer (Age 58)
- Mr. Michael G. Howley, VP & GM of Global Sales (Age 55)
- Mr. William J. Bolt, Exec. Officer (Age 67)
- Mr. Ian McLeod, VP & Corp. Controller
Who are ABIOMED's major shareholders?
ABIOMED's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (10.29%), BlackRock Inc. (7.47%), Primecap Management Co. CA (6.90%), Renaissance Technologies LLC (5.36%), Baillie Gifford & Co. (4.89%) and Brown Capital Management LLC (2.99%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Martin P Sutter, Michael G Howley, Michael R Minogue and William J Bolt. View Institutional Ownership Trends for ABIOMED.
Which major investors are selling ABIOMED stock?
ABMD stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Vanguard Group Inc., Marshall Wace North America L.P., Rathbone Brothers plc, CIBC Private Wealth Group LLC, Victory Capital Management Inc., Janus Henderson Group PLC and Janus Henderson Group PLC. Company insiders that have sold ABIOMED company stock in the last year include Andrew J Greenfield, David M Weber, Martin P Sutter and Michael G Howley. View Insider Buying and Selling for ABIOMED.
Which major investors are buying ABIOMED stock?
ABMD stock was bought by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., William Blair Investment Management LLC, Renaissance Technologies LLC, BlackRock Inc., Thoroughbred Financial Services LLC, Villere ST Denis J & Co. LLC, Nuveen Asset Management LLC and Bessemer Group Inc.. View Insider Buying and Selling for ABIOMED.
How do I buy shares of ABIOMED?
Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ABIOMED's stock price today?
One share of ABMD stock can currently be purchased for approximately $193.01.
How big of a company is ABIOMED?
ABIOMED has a market capitalization of $8.76 billion and generates $769.43 million in revenue each year. The medical equipment provider earns $259.02 million in net income (profit) each year or $3.60 on an earnings per share basis. ABIOMED employs 1,371 workers across the globe.View Additional Information About ABIOMED.
What is ABIOMED's official website?
How can I contact ABIOMED?
ABIOMED's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]
MarketBeat Community Rating for ABIOMED (NASDAQ ABMD)
MarketBeat's community ratings are surveys of what our community members think about ABIOMED and other stocks. Vote "Outperform" if you believe ABMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
